SS-31 Restores Mitochondrial Function to Boost Bone Formation in Aged Cells

As we age, the ability of our bone marrow stromal cells (BMSCs) to differentiate into bone-forming cells (a process called osteogenic differentiation) declines, contributing to conditions like osteoporosis and impaired bone regeneration. This age-related decline is often linked to mitochondrial dysfunction and increased oxidative stress. However, the exact mechanisms and potential therapeutic targets to counteract this decline remain elusive, particularly how specific compounds might restore cellular vitality and enhance bone-forming capacity. This study specifically addresses how SS-31, a mitochondrial-targeted peptide, can improve osteogenic differentiation in aged BMSCs by modulating NOS2 and restoring mitochondrial health.

The study revealed that SS-31 treatment significantly improved the osteogenic potential of aged BMSCs. Specifically, SS-31 at 500 nM reduced the elevated expression of NOS2 (inducible Nitric Oxide Synthase, an enzyme linked to inflammation and cellular stress) by approximately 45% (p<0.01) in aged BMSCs. This reduction was accompanied by a marked improvement in mitochondrial function, with mitochondrial membrane potential increasing by ~30% and cellular ATP production rising by ~25% compared to untreated aged cells. Furthermore, SS-31 treatment led to a significant decrease in intracellular reactive oxygen species (ROS) levels by ~35%. The most striking finding was the 2.5-fold increase in alkaline phosphatase (ALP) activity and a 3-fold enhancement in mineralization (calcium deposition) in aged BMSCs treated with SS-31, indicating robust osteogenic differentiation. Expression of key osteogenic genes like RUNX2, OSX, and OCN also showed a 1.8 to 3.2-fold upregulation.